Lyophilization strategies for development of a high-concentration monoclonal antibody formulation: Benefits and pitfalls

American Pharmaceutical Review

Volumn 13, Issue 1, 2010, Pages 31-38

  Bhambhani, Akhilesh ^a   Blue, Jeffrey T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

ARTICLE; CRYSTALLIZATION; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; FREEZE DRYING; FREEZING; PATIENT COMPLIANCE; ROOM TEMPERATURE; SHELF LIFE;

EID: 77649211492     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Kohler, G, Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497 (1975).
2. Reichert, JM, Dewitz, MC. Anti-infective monoclonal antibodies: perils and promises of development. Nature Rev. Drug Discov. 5: 191-195 (2006).
3. Lefranc, MP, Giudicelli, V, Kaas, Q, Duprat, E, Jabado-Michaloud, J, Scaviner, D, Ginestoux, C, Clement O, Chaume, D, Lefranc, G. IMGT, the international ImmunoGenetics information system. Nucleic Acids Res. 33: D593-D597 (2005).
4. Reichert, JM, Rosensweig, CJ, Faden, LB, Dewitz, MC. Monoclonal antibody successes in the clinic. Nature Biotechnol. 23: 1073-1078 (2005).
5. Glatz, CE. Modeling of aggregation-precipitation-phenomena. In Aherns, TJ, Manning, MC, eds. Stability of protein pharmaceuticals, 1st edition, New York, Plenum Press. P 135-166 (1992).
6. Treuheit, MJ, Kosky, AA, Brems, DN. Inverse relationship of protein concentration and aggregation. Pharm. Res. 19(4): 511-516 (2002).
7. Minton, AP. Influence of macromolecular crowding upon the stability and state of association of proteins: predictions and observations. J. Pharm. Sci. 94:1668-1675 (2005).
8. Minton, AP. The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media. J. Biol. Chem. 276: 10577-10580 (2001).
9. Liu, J, Nguyen, MD, Andya, JD, Shire, SJ. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution.
10. Shire, SJ, Shahrokh, Z, Liu, J. Challenges in the development of High Protein Concentration Formulations. J. Pharm. Sci. 93: 1390-1402 (2004).
11. Atkinson, EM: Klum, W. Formulations strategies for biopharmaceuticals- ensuring success to market. IDrugs 4: 557-560 (2001).
12. Harris, RJ. Heterogeneity of recombinant antibodies: linking structure to function. Dev. Biol. (Basel) 122: 117-127 (2005).
13. Privalov, PL. Cold Denaturation of proteins. Crit. Rev. Biochem. Mol. Biol. 25: 281-305 (1990).
14. Carpenter, JF, Prestrelski, SJ, Arakawa, T. Separation of freezing- and drying-induced denaturation of lyophilized proteins using stress-specific stabilization. I. Enzyme activity and calorimetric studies. Arch. Biochem. Biophys. 303: 456-464 (1993).
15. Pikal, MJ Lyophilization. In Swarbrick, J, Boylan, J (eds.) Encyclopedia of Pharmaceutical Technology, Marcel Dekker, New York, 1299-1326 (2002).
16. Carpenter, JF, Pikal, MJ, Chang, BS, Randolph, TW. Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice. Pharm Res. 14: 969-975 (1997).
17. Harris, JH, Shire, SJ, Winter, C. Commercial Manufacturing Scale Formulation and Analytical Characterization of Therapeutic Recombinant Antibodies. Drug Dev. Res. Vol. 61: 137-154 (2004).
18. Sarciaux, JM, Mansour, S, Hageman, MJ, Nail, SL. Effects of Buffer conditions on Aggregation of Bovine IgG during Freeze-Drying. J. Pharm. Sci. 12: 1354-1361 (1999).
19. Chang, BS, Kendrick, BS, Carpenter, JF. Surface-Induced Denaturation of Proteins during Freezing and its Inhibition by Surfactants. J. Pharm. Sci. 12:1325-1330 (1996).
20. Blue, J, Yoder, H. Successful lyophilization development of protein therapeutics. Am. Pharm. Rev. 40-44 (2009).
21. Tang, XC, Pikal, MJ. Design of Freeze-Drying Processes for Pharmaceuticals: Practical Advice. Pharm. Res. 2: 191-200 (2004).
22. Pikal, MJ. Freeze-Drying of proteins. Part I: process design. BioPharm 3: 18-28 (1990).
23. Pikal, MJ. Freeze-Drying of proteins. Part II: formulation selection. BioPharm 3: 26-30 (1990).
24. Lueckel, B, Bodmer, D, Helk, B, Leuenberger, H. Formulations of sugars with amino acids or mannitol-influence of concentration ratio on the properties of the freeze-concentrate and the lyophilizate. Pharm. Dev. Technol. 3: 325-336 (1998).
25. Williams, NA, Lee, Y, Polli, GP, Jennings, TA. The effects of cooling rate on solid phase transitions and associated vial breakage occurring in frozen mannitol solutions. J. Parenter. Sci. Technol. 40: 135-141 (1986).
26. Searles, JA, Carpenter, JF, Randolph, TW. Annealing to optimize the primary drying rate, reduce freezing-induced drying rate heterogeneity, and determine Tg' in pharmaceutical lyophilization. J. Pharm. Sci. 90: 872-887 (2001).
27. Pikal, MJ, Shah, S, Roy, ML, Putman, R. The secondary drying stage of freeze drying: drying kinetics as a function of temperature and chamber pressure. Int. J. Pharm. 60: 203-217 (1990).
28. Wang, W. Lyophilization and development of solid protein pharmaceuticals. Int. J. Pharm. 203: 1-60 (2000).
29. Franks, F. Freeze-drying: from empiricism to predictability. Cryo-Letters 11: 93-110 (1990).
30. Middaugh, CR, Gerber-Jenson, B, Hurvitz, A, Paluszek, A, Scheffel, C, Litman, G., Physicochemical characterization of six monoclonal cryoimmunoglobulins: possible basis for cold-dependent insolubility. Proc. Natl. Acad. Sci. U.S.A. 75: 3440-3444 (1978).
31. Dill, KA, Alonso, DOV, Hutchinson, K. Thermal stabilities of globular proteins. Biochemistry, 28: 5439-5449 (1990).
32. Jaenicke, R. Protein structure and function at low temperatures. Philos. Trans. R. Soc. Lond. B Biol. Sci. 326: 535-551 (1990).
33. Franks, F. Solid aqueous solutions. Pure Appl. Chem. 65, 2527-2537 (1993).
34. Chang, BS, Randall, CS. Use of subambient thermal analysis to optimize protein lyophilization. Cryobiology, 29: 632-656 (1992).
35. Hsu, CC, Walsh, AJ, Nguyen, HM, Overcashier, DE, Koning-Bastiaan, H, Bailey, RC, Nail, SL. Design and application of a low-temperature Peltier-cooling microscope stage. J. Pharm. Sci. 85: 70-74 (1996).
36. Kim, AI, Akers, MJ, Nail, SL. The physical state of mannitol after freeze-drying:effect of mannitol concentration, freezing rate, and noncrystallizing cosolute. J. Pharm. Sci. 87: 931-935 (1998).
37. Getlin, LA. Kinetics of Phase transitions in a frozen solution. Dev. Biol. Stand. 74: 93-104 (1996).
38. Ma, X, Wang, DQ, Bouffard, R, MacKenzie, A. Characterization of protein formulation for freeze-drying cycle development. Pharm. Sci. 1 (Suppl.) S543 (1998).
39. Lueckel, B, Helk, B, Bodmer, D, Leuenberger, H. Effects of formulation and process variables on the aggregation of freeze-dried interleukin-6 (IL-6) after lyophilization and on storage. Pahrm. Dev. Technol. 3: 337-346 (1998b).
40. Mackenzie, AP. Basic Principles of Freeze-Drying for Pharmaceuticals. Bull. Parenter. Drug Assoc. 20: 101-130 (1966).
41. Sheehan, P, Liapis, AI. Modeling of the primary and secondary drying stages of the freeze drying of pharmaceutical products in vials: numerical results obtained from the solution of a dynamic and spatially multi-dimensional lyophilization model for different operational policies. Biotechnol. Bioeng. 60: 712-728 (1998).
42. Kramers, HA. Brownian motion in a field of force and diffusion model of chemical reactions. Physica 7: 284-304 (1940).
43. Pikal MJ, Roy, ML, Shah, S. Mass and heat transfer in vial freeze-drying of pharmaceuticals: role of the vial. J. Pharm. Sci. 73: 1224-1237 (1984).
44. Pikal, MJ, Lang, JE. Rubber closures as a source of haze in freeze dried parenterals: test methodology for closure evaluation. J. Parenter. Drug Assoc. 32: 162-173 (1978).
45. Andya JD, Gwee, SC, Liu, J, Shen, Y. U.S. Patent 6,267,958 (2006). Breen, ED, Constantino, HR, Hsu, CC, Shire, SJ. Affects of bulk 46. concentration on reconstitution of lyophilized protein formulations. Pharm. Sci. 1 (Suppl.), S540 (1998).
46. Kataka, M, Robillard, P, Brown, J, Tolman, G. Effects of moisture and lyophilization cycle on aggregation of a monoclonal antibody product. Pharm. Sci. 1 (Suppl.) S543 (1998).
47. Duddu, SP, Zhang, G, Dal Monte, PR. The relationship between protein aggregation and molecular mobility below the glass transition temperature of lyophilized formulations containing a monoclonal antibody. Pharm. Res. 14: 596-600 (1997).